LNTH Q2 2025 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$378M-4.1% YoY

Gross Profit

$241M63.8% margin

Operating Income

$88M23.3% margin

Net Income

$79M20.8% margin

EPS (Diluted)

$1.12

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

$87M

Free Cash Flow

$74M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$949M

Stockholders' Equity

$1.2B

Cash & Equivalents

$696M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$378M	$394M	-4.1%
Gross Profit	$241M	$256M	-5.8%
Operating Income	$88M	$103M	-14.4%
Net Income	$79M	$62M	+26.9%

Revenue Segments

Product

$375M33%

PYLARIFY

$251M22%

Radiopharmaceutical Oncology

$251M22%

Total Precision Diagnostics

$116M10%

DEFINITY

$84M7%

Techne Lite

$25M2%

Strategic Partnerships And Other

$12M1%

Other Precision Diagnostics

$7M1%

License and Royalty Revenues

$3M0%